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Abstract 
Phospholipids comprise a large body of lipids that define cells and organelles by forming 
membrane structures.  Importantly, their complex metabolism represents a highly 
controlled cellular signaling network that is essential for mounting an effective innate 
immune response.   Phospholipids in innate cells are subject to dynamic regulation by 
enzymes, whose activities are highly responsive to activation status.  Along with their 
metabolic products, they regulate multiple aspects of innate immune cell biology, 
including shape change, aggregation, blood clotting, and degranulation. Phospholipid 
hydrolysis provides substrates for cell-cell communication, enables regulation of 
hemostasis, immunity, thrombosis, and vascular inflammation, and is centrally important 
in cardiovascular disease and associated co-morbidities. Phospholipids themselves are 
also recognized by innate-like T cells, which are considered essential for recognition of 
infection or cancer, as well as self-antigens.  This review will describe the major 
phospholipid metabolic pathways present in innate immune cells and summarize the 
formation and metabolism of phospholipids as well as their emerging roles in cell biology 
and disease.  
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Main Text 
 
Circulating innate immune cells, including neutrophils, platelets, monocytes, eosinophils, 
and mast cells, are considered resting basally.  However, they rapidly activate during 
injury, such as bleeding or trauma, to trigger hemostasis and prevent bacterial invasion. 
Major metabolic changes to the lipid pool that accompany innate immune activation are 
essential in orchestrating an effective innate immune response and then initiating the 
process of wound healing and repair. This cellular activation is exemplified by 
multifaceted alterations to the phospholipid (PL) pool and includes: (i) membrane 
remodeling and generation of potent bioactive signaling mediators from PL-derived 
substrates (lysophospholipids (lysoPL), oxylipins, and platelet-activating factor (PAF) 
etc.); (ii) aminophospholipid (aPL) externalization, providing a negatively-charged 
membrane that supports clotting factor activities on the cell surface; (iii) generation of 
large numbers of enzymatically-oxidized PL (eoxPL), which are required for hemostasis, 
immediately upon innate immune cell activation; and (iv) inside the cell, PL headgroup 
phosphorylation that occurs within seconds, leading to formation of transient membrane 
anchors for kinases that regulate GPCR signaling, endocytosis, apoptosis, and 
cytokinesis.  
 
Separate from changes to the PL pool, lipid-reactive T cells restricted to the CD1 family 
of antigen-presenting molecules, can sense the presence of bacterially-derived lipids, 
self-lipids during thymic selection, and self-lipids that may be perturbed during cellular 
stress [1, 2].  Many lipid-reactive T cells appear non-reactive to common phospholipids 
normally found within the cell membrane. However, T cells reactive to bacterially-derived 
phospholipids [3, 4], rare phospholipids [5], and lysophospholipids expressed on certain 
tumors [6, 7] have been described.  These processes will be described in detail below.  
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PLs represent a diverse group of lipids also known as glycerophospholipids (GP, 
described using LIPID MAPS nomenclature).  The five classes are subdivided based on 
polar headgroup and include phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), phosphatidylinositol (PI) and phosphatidylserine (PS).  Within 
each class, molecular species are differentiated by fatty acid (FA) substitution at the sn1 
and sn2 positions of the glycerol backbone (Figure 1A).  Generally, sn1 FAs are saturated 
or mono-unsaturated, whereas sn2 are polyunsaturated (PUFA) with longer acyl chains.  
While the sn2 FA is always an acyl substituent, the sn1 for PE or PC can be either an 
alkyl-linked (ether-linked) or 1Z-alkenyl-linked (plasmalogen), with the latter particularly 
abundant in circulating immune cells (Figure 1B).   Thus, blood cells contain literally 
hundreds of unique PL species, although the most quantitatively abundant contain a 
relatively restricted set of FAs: palmitic acid (PA, 16:0), stearic acid (SA, 18:0) or oleic 
acid (OA, 18:1) at sn1, and linoleic acid (LA, 18:2), arachidonic acid (AA, 20:4), 
eicosapentaneoic acid (20:5, EPA) or docosahexanoic acid (22:6, DHA) at sn2 (Figure 1 
C,D).  Overall, AA is present in PLs at least at 10-fold higher concentrations than other 
PUFAs at sn2 in immune cells.  Dietary intake of fatty acids, through ingesting high doses 
of fish oils, can influence relative levels of omega 3 (DHA, EPA) versus omega 6 (AA, LA) 
fatty acids in blood cell PLs[8, 9]. Whether this leads to changes in PL-mediated signaling 
in the innate immune system is unknown.  However it has knock-on effects on levels of 
oxylipins generated in serum, with higher levels of some omega3 derived species 
observed [10-15].    
 
Phospholipids are synthesized and remodeled through several interconnected enzyme 
pathways, including the Kennedy pathway (PC, PE synthesis), the cytidine diphosphate 
diacylglycerol (CDP-DAG) pathway (synthesis of PS and PI from PA), and the Lands 
cycle (FA removal and reattachment to PLs) (Supplementary Figure 1 A,B) [16-18].  
These are common to all cell types, including circulating blood cells, and are subject to 
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dynamic regulation depending on metabolic state.  The Lands cycle controls substrate 
supply for bioactive lipid signaling and is described in more detail below.  
 
Following an acute injury, circulating cells become trapped at the wound site. The 
resulting clot composition is highly dependent on vessel type and co-existing inflammation 
[19-21].  Concurrently, trapped cells are exposed to soluble protein and non-protein 
mediators that activate receptor-dependent processes, including tissue factor, collagen, 
thrombin, ADP, damage-associated molecular patterns (DAMPs), and pathogen-
associated molecular patterns (PAMPs).  PAMPs include bacterial products such as 
lipopolysaccharide (LPS) and f-met-leu-phe (fMLP), both of which stimulate cells in the 
nanogram range. LPS acts via TLR complexes, while fMLP mediates signaling via a 
GPCR called FPR1.   At the same time, a cascade of cell activation processes 
characterized by extracellular calcium influx and release from intracellular stores are 
associated with PL hydrolysis. This is mediated by several types of phospholipases, 
broadly categorized as PLA1, PLA2, PLC, PLD and named by site of PL hydrolysis. Each 
comprises families of multiple isoforms (Figure 2 A).  Many different phospholipases are 
acutely switched on in activated blood cells, and their coordinated activities are 
responsible for initiating cell activation during the injury response.  This controls much of 
the signaling that leads to lipid membrane remodeling and a plethora of lipid-dependent 
bioactivities, both intracellular and extracellular.  Lipids generated during initial 
phospholipase activity are either released as secondary paracrine mediators (e.g. 
oxylipins), or retained in the cells to act locally, either physically changing membrane 
structure (e.g. eoxPL) or signaling at intracellular nuclear receptors (e.g. FA activation of 
PPARs).  The following sections describe PL metabolism in innate immune cells in more 
detail.   
 
1. PLA2-mediated phospholipid hydrolysis forms lysoPL and FAs. 
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Pathophysiological activation of innate cells triggers immediate cell membrane hydrolysis 
by phospholipases. The best studied are PLA2 isoforms, which comprise ~16 groups and 
several subgroups, with six main PLA2 subtypes [22].  PLA2 removes fatty acyl groups 
from the sn2 position of PL, leading to lysoPL and FA generation and thereby supporting 
the first step in bioactive oxylipin formation (Figure 2 A). Several lysoPLs are generated 
during platelet activation, including lyso-PE, -PC, -PI and –PS [23]. Leukocytes and 
platelets express at least three classes of PLA2: secretory (sPLA2, Groups II and X), 
calcium-dependent (cPLA2, Group IV), and calcium-independent (iPLA2, Group VI), whilst 
several others are known to exist in other cells.  Another PLA2 isoform, termed PAF-acetyl 
hydrolase (PAF-AH), is found in the circulation [24].   
 
Regulation of innate immune cell PLA2 is multifaceted and complex. For example, in 
monocytes, both MAPK-catalyzed phosphorylation and PKC activate cPLA2 [25]. For 
many years, cPLA2 was considered the primary source of AA for eicosanoid generation, 
but recent studies show a major role for iPLA2 in several circulating cell types.  In this 
regard, platelet cPLA2 can catalyze AA release from innate immune PL pools in 
response to collagen, enabling generation of thromboxane A2 and 12-HETE [26].  
However, iPLA2 is required to mobilize AA from plasmalogen PEs and PGs for ADP-
induced thromboxane B2 generation [27]. Thus, different PLA2 isoforms couple to distinct 
receptor pathways, though both can facilitate platelet eicosanoid generation.  Similarly, in 
leukocytes, cPLA2 and iPLA2 act together to provide different signaling lipids at 
separate intracellular sites, with both required for migration in response to MCP-1 (also 
known as CCL2) [28].   
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Importantly, PLA2 provide the essential link between PL metabolism and cyclooxygenase-
mediated (COX-mediated) pathways in immune cells, e.g. generation of thromboxane in 
platelets, and prostaglandin E2 (PGE2) in inflammation, both of which require AA.  COX-
1 and COX-2 are the well-known targets of aspirin, non-steroidal anti-inflammatory drugs 
(NSAIDs), and more recently-developed COX-2-selective NSAIDs, underscoring their 
clinical importance in vascular and chronic inflammatory disease.     
 
Circulating blood cells express several sPLA2 isoforms, including Group IIA (platelets, 
leukocytes), Group X (neutrophils), and Group III (mast cells).  Group IIA sPLA2 attacks 
bacterial membranes during host defense in innate immunity, while Group III targets 
stromal fibroblasts. PG and PE are the primary targets of Group IIA, with host cells being 
relatively protected since PC comprises most of the external membrane leaflet of healthy 
cells. In contrast, in mast cells, Group III sPLA2 attacks stromal cells via AA release and 
its metabolism to prostaglandin D2, promoting mast cell maturation and ultimately 
anaphylaxis [29].   
 
Hydrolysis of the sn1 fatty acyl group can also result in lysoPL and FA release, in this 
case due to PLA1 (Figure 2 A).  Little is known about PLA1 in immune cells, although a 
fast release of saturated FAs occurs upon platelet activation [30]. A platelet PLA1 isoform 
was purified in 2011 and proposed as a source of circulating lysoPA generated during 
clotting, acting in concert with autotaxin to mediate sequential hydrolysis of cellular PC 
[31].  
 
Regulation of PLA2 isoforms in innate immune cells is complex, given the large number 
of gene products, varied cell expression, intracellular localization, activation, control, etc.  
For further information on this topic, the reader is directed towards several recent reviews 
[25, 29, 32].   
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Phospholipases and their products play multiple and complex roles in disease, with 
symptoms noted well beyond the innate immune system.  Deficiency of cPLA2 in 
humans leads to major gastrointestinal complications including bleeding, as well as 
increased susceptibility to infection, and acute respiratory distress syndrome. A lack of 
platelet thromboxane B2 is associated with platelet defects[25].  On the other hand, mice 
lacking cPLA2 are protected from hepatic liver deposition and fibrosis[25].  Deficiency of 
iPLA2 is linked with several diseases including neurological, cancer, vascular and 
immune[32].  In terms of inflammation, iPLA2 is required for macrophage 
spreading/adhesion[32].  Inhibitor studies have shown that cPLA2 and iPLA2 isoforms are 
critical for development of autoimmune disease, such as experimental autoimmune 
encephalomyelitis[32].   
 
 
2. Scramblase activities leading to aPL externalization. 
 
Normally, circulating blood cells maintain an asymmetric plasma membrane with PC the 
most abundant externally-facing PL and PE/PS primarily located on the cytosolic surface.  
PE and PC each make up about 40% of total PL in blood cells, with PS being only a few 
mol % [33, 34].  Maintaining asymmetry is an energy-requiring process utilizing flippase 
and floppase enzymes to prevent exposure of the negatively-charged aminophospholids 
(aPL) PS and PE on the outside of the cells.   Upon activation and calcium mobilization, 
platelets rapidly activate scramblase, leading to externalization of aPL (Figure 2B) [35, 
36].  This changes the biophysical nature of the membrane to allow coagulation factors 
to bind and work effectively to generate fibrin.  A genetic defect in aPL externalization has 
been described, Scott Syndrome, that manifests as a relatively mild bleeding 
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phenotype[37].  This has been localized to mutations in TMEM16F, a protein proposed to 
play dual roles as both a channel and scramblase[38] 
 
Coagulation factors comprise a series of serine proteases and associated co-factors that 
are largely inactive in the fluid phase of blood.  In order to facilitate clot formation, they 
must self-associate on a negatively-charged surface, where they reach a high local 
concentration.  This is classically achieved by platelets externalizing PE/PS following 
agonist activation [35, 36].  The headgroup of PS facilitates calcium binding to the surface, 
which ultimately allows binding of negatively-charged gamma-carboxyglutamic (Gla) 
domains of factors at the cell membrane (Figure 2B).  The ability of PS to support Gla-
domain-binding is enhanced by PE and eoxPL, a recent discovery that is described in 
more detail later [39, 40].  Platelets contain several molecular species of PE and PS.  The 
optimum FA composition to support coagulation is around 18-20 carbons, with typical 
unsaturation seen in platelet PLs, though plasmalogen and acyl forms of PE are equally 
effective in this context [41]. Recent studies show that PE and PS associate on the 
surface of platelets in defined microdomains, forming “cap” structures [42]. This may 
further enhance hemostasis by reducing the surface area available, leading to higher local 
concentrations of coagulation factors on the cells.  
 
PE/PS externalization is often measured using annexin V, which binds to negatively-
charged membranes via electrostatic interactions, similarly to coagulation factors [43-45].  
Often, annexin V positivity is described as PS externalization, but it can also bind PE.  
Another protein, lacthadherin, is reportedly PS-specific [46, 47].   During inflammation, 
apoptotic innate immune cells can lose membrane asymmetry, also leading to PE/PS 
externalization [34].  This is particularly relevant in the case of neutrophils, which undergo 
apoptosis following infection.  Neutrophil apoptosis occurs alongside elevated 
 9 
coagulation during systemic infection and sepsis, suggesting a mechanistic link between 
neutrophil aPL exposure and associated coagulation [48].  
 
3. Generation and action of eoxPL in innate immunity.  
 
Oxidized PCs with truncated FAs containing reactive aldehydes at the sn2 position have 
long been known to be generated non-enzymatically [49-52].  They are detected in 
atheroma lesions and in the circulation during a myocardial infarction caused by plaque 
rupture [53]. In contrast, several families of enzymatically-oxidized PL (eoxPL), 
comprising eicosanoids/prostaglandins attached to PLs, were recently discovered.  
Circulating blood cells (neutrophils, platelets, eosinophils) and resident murine peritoneal 
macrophages generate eoxPL in a controlled manner by as part of the innate immune 
response [40, 54-59]. They form via the catalytic activities of lipoxygenases (LOX) as well 
as COX-1 (Supplementary Figure 2A).  The most abundant eoxPL are PEs, but PC forms 
are also found, and low levels of PI analogs were recently detected in platelets [60].  PC 
and PE eoxPL form as both plasmalogen and acyl species.  
 
For many years, LOX isoforms were best known to generate monohydroperoxide 
derivatives of free-acid PUFAs, primarly AA (HpETEs), but also DHA (HpDOHEs) and LA 
(HpODEs). Cellular glutathione peroxidases (GPx) rapidly reduce lipid hydroperoxides to 
form hydroxyeicosatetraenoic acids (HETEs), hydroxydocosahexanoic acids (HDOHEs), 
and hydroxyoctadecadienoic acids (HODEs), respectively. Positional isomers of these 
are generated in a cell-specific manner due to LOX expression patterns, e.g. by 5-LOX 
(5-HETE in neutrophils, monocytes), 15-LOX (15-HETE, 17-HDOHE in human 
eosinophils), and 12-LOX (12-HETE, 14-HDOHE in platelets).  In mice, 15-LOX is 
represented by a 12/15-LOX gene product, with a similar expression pattern to human 
cells, that generates primarily 12-HETE and 14-HDOHE.  This isoform is also highly 
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expressed in murine peritoneal macrophages and is inducible by Th2 cytokines.  Since 
AA is present in PL in at least 10-fold higher concentrations in immune cells than other 
PUFAs, its monohydroxylated products are the most abundant; for example, 12-HETE is 
the predominant eicosanoid generated by human platelets.   
 
Most LOXs will only utilize free-acid PUFA due to steric hindrance at the active site; 
however, the 15-LOX (12/15-LOX in mice) can uniquely utilize oxidize PLs [61].  Thus, 
eoxPLs generated via 5- or 12-LOXs require a cycle of hydrolysis and re-esterification, 
involving PLA2 and MBOAT/LPAT activities, while those from the 15- or 12/15-LOX do 
not (Supplementary Figure 2B) [40, 56, 58].  This is consistent with observations that 
neutrophil or platelet HETE-PLs are generated following agonist activation of cells to 
trigger PLA2, while eosinophil/macrophage HETE-PLs are detected under basal 
conditions [40, 56, 58, 59].  Similarly, eoxPL containing COX-1 products, such as 
prostaglandin E2–PEs, require a cycle of hydrolysis and re-esterification [54].   
 
Circulating innate immune cells and platelets generate eoxPL via coordinated signaling 
pathways mediated by receptor-dependent calcium mobilization within 2-5 minutes of 
activation [40, 54, 56].   Unlike free-acid oxylipins, the cells retain eoxPL within the 
membrane compartment and do not secrete them, suggesting a different biological role 
to their free analogs. Up to 2016, only small numbers of eoxPL were known, typically 4-6 
per cell type. However, studies using high-resolution lipidomics recently showed that 
human platelets generate over 100 unique molecular forms [30].  The most abundant are 
12-HETE-PLs, in line with the relative abundance of platelet 12-HETE.  However, multiple 
oxidized forms of AA are detected in platelet eoxPL, along with mono-hydroxylated forms 
of rarer FAs (DHA, EPA, and others) [30]. EoxPLs that contain thromboxane B2 have 
never been detected, despite the abundance of this platelet lipid, suggesting that not all 
oxylipins are substrates for re-esterification.  A recent study demonstrated that specific 
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eicosanoids serve as substrates for acyl-CoA synthetases, which activate eicosanoids to 
produce an eicosanoid-CoA species. This eicosanoid-CoA species then can be utilized 
by an acyltransferase (like MBOATs) to esterify the eicosanoid into PL species, indicating 
that cellular control of eoxPL formation may occur at the level of esterification [62].  
Furthermore, correlation analysis of eoxPL from platelets shows clustering into 
structurally-related groups, further supporting the idea that their formation is dictated at 
least in part by the oxidized FA structure and resulting specificity of esterification 
pathways [39].    
 
eoxPLs display multiple biological activities relevant to innate immunity and inflammation 
regulation.  In neutrophils, HETE-PEs promote antibacterial activities, including 
enhancing IL-8 release and NET formation, while macrophage KETE-PEs are low affinity 
agonists for PPAR [56, 57]. Recently, HETE-PEs and -PCs were shown to be potently 
pro-coagulant due to their enhancement of PS binding to coagulation factors 
(Supplementary Figure 3A) [39]. In this, the lipids’ oxidation epitope enhances the overall 
electronegative character of the plasma membrane, facilitating calcium interactions with 
PS that are required for blood clotting.  Related to this, eoxPL are significantly elevated 
in circulating cells in patients with the thrombotic disorder antiphospholipid syndrome 
(aPLS), and mice lacking either platelet or eosinophil LOX isoforms display a venous 
bleeding defect that can be corrected by eoxPL administration [39, 63].  eoxPL also are 
immunogenic in vivo, with elevated eoxPL-specific IgG detected in aPLS patients [39].  
 
4. PAF, a plasmenylcholine with potent signaling activities 
 
PAF is a structurally unique plasmenylcholine (alkyl bond at sn1) with an acetyl group at 
the sn2 position that signals at extremely low concentrations (around 10–14 M) via the PAF 
receptor, a GPCR, stimulating multiple signaling cascades (Supplementary Figure 3B).  
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The PAF receptor is expressed by numerous blood cells including neutrophils, 
monocytes, eosinophils, and platelets [64].  It triggers multiple biological actions, including 
aggregation, calcium mobilization, superoxide release, eicosanoid generation, 
chemotaxis, adhesion, and cytokine generation in multiple circulating cell types, including 
platelets, neutrophils, and eosinophils [65].   
 
PAF is generated via both remodeling and de novo pathways [66, 67] (Supplementary 
Figure 3B).  Remodeling is the prominent biological mechanism and involves replacing 
an acyl with an acetyl moiety at the sn2 position.  De novo generation involves acetylation, 
dephosphorylation, and PC addition to a lysoPA, with this last step thought to be the 
source of endogenous PAF for homeostatic functions [67]. 
 
Two enzymes are involved in dynamically modulating PAF levels in the circulation.  An 
acetyl transferase generated by circulating neutrophils and monocytes metabolizes lyso-
PAF to PAF through addition of an acetyl group at the sn2 position.  This is the prominent 
source of PAF during inflammation and allergies [68].  On the other hand, PAF is removed 
by the action of PAF acetyl hydrolase (PAF-AH), a circulating enzyme generated by 
multiple cell types, including innate immune blood cells.  Platelets are also a source of 
PAF that is generated during aggregation.   
 
Several studies have evaluated the potential for circulating PAF to act as a 
biomarker/predictor of cardiovascular disease or events.  Despite its association with 
higher disease burden, PAF-AH itself may represent a target for cardiovascular 
prevention, since PAF metabolism can lead to generation of pro-inflammatory lipids, such 
as lysoPC and lysoPAF.  This concept led to extensive evaluation of reversible PAF-AH 
inhibitors, such as darapladib, in trials; however, these yielded mixed results, lacking 
sufficient affect on primary endpoints [24].    
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5. PLC in innate immune signaling.  
 
PLCs are a class of enzymes that cleave PLs on the glyceride side of the phosphodiester 
bond, leading to diacylglycerol (DAG) formation and release of the phosphorylated PL 
headgroup (Figure 3A). PI-specific PLCs are the most important PL in immune cells, 
comprising approximately thirteen enzymes represented by six isotypes that play key 
roles in signal transduction [69].  PI-PLC hydrolyses PI-4,5-bisphosphate (PIP2) to form 
DAG and Ins(1,4,5)P3, which in turn can activate PKC and mobilize intracellular calcium, 
respectively to regulate both acute and chronic responses in immune cells.  PLCs are 
activated by GPCRs and tyrosine kinase-linked receptors (RTKs) in platelets and 
leukocytes. RTK-activated PLC subtypes are the most important in these cells, playing 
key roles in supporting neutrophil respiratory burst, phagocytosis, adhesion, and cell 
migration. PLC2 is important for hemostasis: mice lacking this isoform exhibit a bleeding 
defect, with glycoprotein VI- and CLEC-2-dependent platelet responses abolished [70-
74].   This isoform also plays a role in platelet-dependent clot retraction [75]. Mast cells, 
NK cells, and murine neutrophils express both PLCγ1 and PLCγ2 isoforms [76-79].  In all 
these cells, these PLC isoforms modulate TLR signaling through multiple mechanisms 
(reviewed in [80]).  In addition, several GPCR-activated PLCβ isoforms have been 
detected in immune cells, with these playing key roles in the differentiation and activation 
of both innate and adaptive immune responses, with increases in free calcium and PKC 
activity being essential [69, 81]. Recently, PLCδ was shown to act as a negative regulator 
of macrophage-mediated phagocytosis [82].   
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6. PLD signaling in innate immune cells. 
 
PLD enzymes hydrolyze PC, the most abundant external-facing PL, generating 
phosphatidic acid (PA) and choline (Figure 3A).  They are activated in response to several 
GPCRs and RTKs (reviewed in: [83]). PA has a number of critical functions in innate 
immune signaling.  With a small, negatively-charged headgroup, PA induces negative 
curvature thought to be important for production of vesicles and membrane fusion, thus 
playing a central role in membrane remodeling [84]. PA also acts as an intracellular signal, 
binding several cellular proteins including the GEFs DOCK2 and SOS, which activate 
Rac1 and Ras, whilst the PA-binding domain of cyclicAMP-PDE4A1 has been clearly 
defined[85-87]. Innate immune cells and platelets express the isomers PLD1 and PLD2, 
both known to play key roles in thrombotic disease [88-91].  Pld1-/- mice exhibit reduced 
αIIbβ3-dependent platelet activation, rendering them resistant to pathological hemostasis 
events such as strokes and pulmonary embolisms [92]. Studies in knockout mice and the 
use of isoform-specific inhibitors indicated that PLD1, but not PLD2 is required for 
neutrophil ROS production[93]. The concerted action of PLD and PLA2 leads to formation 
of lysoPA, generated by thrombin-stimulated platelets, and is potentially able to stimulate 
aggregation itself via GPCR signaling [94] (Figure 6A); this is in addition to lysoPA 
generated by the action of autotaxin (lyso-PLD) upon lysoPC.  
 
 
7. Phosphoinositides :   
The seven phosphoinositides (PI(3)P, PI(4)P, PI(5)P, PI3,4P2, PI(4,5)P2, PI(3,5)P2 and 
PIP3) each demonstrate signaling capabilities (Figure 3B). The phosphoinositide 3-
kinase (PI3K) enzymes catalyze hydroxyl group phosphorylation at the 3-position of the 
inositol headgroup of PI and its phosphorylated derivatives. The eight mammalian PI3K 
enzymes sort into three groups: Class I (PI3K   ), Class II (PI3KC2  ) and Class 
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III (vps34). Class I PI3Ks phosphorylate PIP2 to generate phosphatidylinositol 3,4,5-
trisphosphate (PIP3). Class II enzymes can phosphorylate both PI or PI4P to generate 
PI3P or PI(3,4)P2 on endosomes and the plasma membrane. Finally, Class III enzyme 
solely phosphorylates PI, producing PI(3)P on endosomes, which also plays a key role in 
autophagy [95].  
 
Class IA PI3Ks (PI3K and PI3K) are ubiquitously expressed, whilst PI3K is restricted 
to myeloid and lymphoid cells (reviewed in [96]). The Class IB isoform, PI3K is 
differentially expressed, but is most highly expressed in myeloid cells. Each Class IA 
PI3K  and  comprises one of five homologous regulatory subunits (p85, p85, 
p50, p55 or p55) complexed with a single p110 subunit, whereas PI3K is made up 
of p110 and either a p84 or p101 regulatory subunit. The soluble PI3Ks are recruited to 
the plasma membrane following receptor occupation. Antigen receptors, Fc receptors, 
integrins, cytokine receptors, and RTKs such as colony-stimulating factor (CSF) stimulate 
PI3K,  and  activity through tyrosine phosphorylation with the SH2 domains in the 
regulatory domain, binding to the phosphotyrosine residues. GPCRs such as fMLP 
activate PI3K through G subunits binding to p84 or p101 and to p110. G has also 
been shown to bind to and thus activate p110. Membrane association is further 
promoted by binding of the Ras-binding domain of the p110 subunits, associating with 
either Ras (p110  ) or Rac (p110). 
 
PI3K activity generates PIP3, which binds to PH domains in target proteins and activates 
signaling cascades. The phosphorylation and activation of the serine kinase PKB (also 
known as AKT) is an ubiquitous response to PI3K activation that can activate TORC1 to 
promote cell growth, but also activates a metabolic shift, as in CTL activation [97]. PKB 
also phosphorylates and inhibits the nuclear localization of FOXO transcription factors 
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critical in lymphocyte differentiation. PIP3 is dephosphorylated to regenerate PI(4,5)P2 
by PTEN, but can also generate PI(3,4)P2 through SHIP1/2 activity [98]. PI(4,5)P2 also 
binds PH domain-containing proteins and, whilst many of these also bind PIP3, there is 
PI(3,4)P2 selectivity notably DAPP-1 [96]. Lipidomic analysis has shown that PIP3 is not 
a single molecular species, with C36:1, C36:2, C36:3, C36:4, C38:2, C38:3, C38:4 and 
C38:5 being detected in neutrophils and macrophages [99, 100]. This variety may enable 
further selectivity in binding of different PH-domain proteins and thus downstream 
signaling [100] 
 
The field’s understanding of the distinct roles of PI3K isoforms has benefited from 
generation of knockout mice and selective small molecule inhibitors. These approaches 
have provided evidence that PI3K is critical for extravasation and migration of 
neutrophils, monocytes, and eosinophils to inflammatory sites, with additional PI3K 
involvement possibly occurring through integrin-mediated activation. PI3K and  
regulate immune cell spreading and activation by mediating cell surface attachment to 
extracellular matrix or pathogens, such as fungi, and both isoforms are necessary for a 
maximal ROS response [101]. In addition, PI3K activity stimulates Rac through PIP3 
regulation of GEFs and GAPs, leading to regulation of the actin cytoskeleton. 
 
The development, proliferation, and differentiation of B and T cells are stringently 
regulated by PI3K activity, which involves PIP3-regulated signaling, including control of 
FOXO/FoxP3. However, PIP3 also activates BTK, which phosphorylates and stimulates 
PLC-producing DAG and calcium signaling that are important for both B cell proliferation 
and cytokine synthesis [102]. There has been extensive development of PI3K inhibitors, 
with a number approved for clinical use [103], particularly PI3K inhibitors to treat chronic 
lymphocytic leukemia [104]. The importance of the PI3K pathway in human immune 
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disorders is further emphasized by the presence of activating mutations in p110 in a 
number of primary immune deficiency patients, who suffer particularly from recurring 
respiratory tract infections [105]. In contrast, deficiency in PI3K signaling decreases Treg 
cell number and increases neutrophil numbers, which can cause an increase in endotoxic 
shock-related mortality [106]. 
 
8. Phospholipids as ligands for innate-like T cell populations. 
 
Most immunologists consider T cell immunity only in the context of peptide recognition 
when presented by MHC molecules [107].  However, the family of MHC class I-like 
antigen-presenting molecules termed CD1 is ideally suited for capturing and displaying 
lipids for T cell surveillance [2].  This evolutionarily-conserved CD1 antigen-presenting 
family is sub-divided into group 1 (CD1a, CD1b, and CD1c) and group 2 (CD1d) 
members.  CD1 group 1 is absent in mice, thus our understanding of their role in immunity 
is less developed than CD1d, which is present in mice and humans [108, 109].  Each 
CD1 isoform has distinct atomic architectures [110] and cellular trafficking properties, 
thereby enabling broad array of lipid classes (including PLs) that can either represent 
foreign or self-antigens to be bound.   
 
Distinct populations of T cells subsequently recognize these CD1-lipid complexes.  Lipid-
reactive T cells play key roles in protective immunity, cancer, autoimmunity, and allergies. 
The most well-characterized lipid-reactive T cells are the innate-like type I Natural Killer 
T cells (NKT cells), which are restricted to the CD1d molecule [2].  Type I NKT cells rapidly 
secrete high amounts of a range of cytokines upon activation and have shown broad 
therapeutic promise [109]. 
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Lipid-reactive T cells can specifically respond to a range of CD1-presented lipids, 
including PLs, a major lipid component of mammalian membranes.  Indeed, subsets of 
type I NKT cells have exhibited autoreactivity towards PI, PE, and plasmalogen lysoPE 
(p-lysoPE) [111, 112] [113].  While the physiological role of NKT autoreactivity towards 
common PLs remain unclear, reactivity towards certain lysoPLs, including lysoPC, are 
reported to be associated with inflammatory responses [114]. Interestingly, p-lysoPE is 
an ether-linked PL that is generated in the peroxisome and thought to play a role in the 
development of NKT cells [115].  Further, infection by Hepatitis B virus (HBV) alters the 
levels of lipids, including lysoPLs within hepatocytes, which subsequently results in NKT 
cell activation, thereby playing a role in protective immunity [116]. 
 
The functional properties, T cell receptor (TCR) repertoire, and antigen reactivity of type 
II NKT cells are distinct from type I NKT cells [1]. Type II NKT cells are also described as 
responsive to bacterially-derived PLs, including PI and PG from M. tuberculosis, 
suggesting a role in protective immunity towards this devastating pathogen [4]. PG from 
Listeria monocytogenes was also shown to potently activate a subset of type II NKT cells 
[3]. 
  
Members of CD1 group 1 also present PLs, and T cell reactivity towards certain pollen-
derived PLs has been associated with allergies [117, 118].  Further, CD1a, which is 
expressed predominantly in the skin and naturally present skin-derived oils [119], is 
associated with contact hypersensitivities [120] as well as bee sting allergies due to 
phospholipase activity derived from bee venom-generating LPLs that cause an 
inflammatory skin response [121, 122].  Moreover, aberrant reactivity towards CD1a-
presented PLs is also implicated in allergies towards house dust mites [123].  CD1b-
mediated autoreactivity towards rare mammalian PLs, including PG, have also recently 
been described and implicated in some autoimmune conditions [124] [125].   
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The conundrum of how lipid-reactive T cells distinguish between rare and common PLs 
was recently determined to arise from the ideal shape and charge complementarity 
between the TCR and CD1b-PG complex, whereas the polar headgroups of more 
common PLs are sterically-disfavored from binding to the TCR [5].  Further, T cell 
targeting of specific PLs, including methyl-lysophosphatidic acid (mLPA), when presented 
by CD1c+ leukemic cells is considered to play a role in anti-tumor immunity and hence 
may represent a likely candidate for novel immunotherapeutic approaches [6].  
Collectively, T cell reactivity towards CD1-restricted PLs is emerging as a component of 
protective and aberrant immunity, although the breadth of reactivity towards distinct PLs 
and their role in physiology and pathophysiology remains germinal. 
 
9. Summary  
Herein, we summarized the major PL-dependent signaling pathways in circulating innate 
immune cells and their recognition by specialized populations of innate T cells during 
challenge.  The importance of PLs in the acute response to injury extends far beyond 
their structural role, as they provide a major repository for activation-dependent signaling 
molecules such as PGs, oxylipins, and PAF during acute injury and inflammation and 
through T cell recognition, representing a way for the body to sense danger and 
appropriately respond during challenge.  Importantly, PL-dependent signaling is not only 
mediated through long-known soluble paracrine mediators (oxylipins such as 
prostaglandins), but also through changing membrane biophysics that alter protein 
binding and activation both on the outside and inside of cells (eoxPL, phosphoinositides).  
Many questions remain in the emerging study of PL signaling, particularly relating to how 
PLs dynamically change, the role(s) of CoA-dependent versus –independent recycling 
pathways in their metabolism, how tissues recognize endogenous changes and respond, 
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and ultimately how to harness these processes to improve detection, diagnosis, and 
treatment of human disease associated with aberrant PL generation and signaling.  
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Figure Legends 
 
Figure 1. Structures of the major PL classes.  Panel A. The five phospholipid classes 
are shown: PS: phosphatidylserine, PI: phosphatidylinositol, PG: phosphatidylglycerol, 
PE: phosphatidylethanolamine, PC: phosphatidylcholine.  Panel B. Ether and 
plasmalogen PLs.  Panels C,D. Structures of the common fatty acids in PLs.  
 
Figure 2. PL cleavage and PL asymmetry in innate immune cells.  Panel A. 
Phospholipases hydrolyze PLs and are named by the site of hydrolysis, as shown.  Panel 
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B. Platelets externalize PE and PS on activation, providing a negatively charged surface 
that supports coagulation factor binding via calcium-dependent mechanisms.  
 
Figure 3. PLC, PLD and Phosphoinositide pathways. Panel A. PLC and PLD generate 
lipid intermediates that promote innate immunity.  Panel B. PI is 
phosphorylated/dephosphorylated by a series of known enzymes, generating a complex 
array of transient lipid molecular species which display potent bioactivity.   
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